November 17, 2016 - By Clifton Ray · 0 Comments
The stock of Tenax Therapeutics Incorporated (NASDAQ:TENX) registered a decrease of 0.38% in short interest. TENX’s total short interest was 764,100 shares in November as published by FINRA. Its down 0.38% from 767,000 shares, reported previously. With 41,900 shares average volume, it will take short sellers 18 days to cover their TENX’s short positions. The short interest to Tenax Therapeutics Incorporated’s float is 4.54%. About 15,844 shares traded hands. Tenax Therapeutics Inc (NASDAQ:TENX) has declined 49.08% since April 15, 2016 and is downtrending. It has underperformed by 53.70% the S&P500.
Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The company has a market cap of $39.16 million. The Firm is focused on identifying, developing and commercializing products for the critical care market. It currently has negative earnings. The Company’s main product is levosimendan.
Tenax Therapeutics, Inc., incorporated on April 17, 2008, is a specialty pharmaceutical company. The Firm is focused on identifying, developing and commercializing products for the critical care market. The Company’s main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions.
More recent Tenax Therapeutics Inc (NASDAQ:TENX) news were published by: Businesswire.com which released: “Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan” on October 05, 2016. Also Businesswire.com published the news titled: “Tenax Therapeutics Highlights Completion of Enrollment for LeoPARDS Trial by …” on December 22, 2015. Businesswire.com‘s news article titled: “Oxygen Biotherapeutics Announces Name Change to Tenax Therapeutics (NASDAQ: TENX)” with publication date: September 16, 2014 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Clifton Ray